www.ijbcp.com International Journal of Basic & Clinical Pharmacology | December 2018 | Vol 7 | Issue 12 Page 2325 IJBCP International Journal of Basic & Clinical Pharmacology Print ISSN: 2319-2003 | Online ISSN: 2279-0780 Original Research Article Comparative study of safety and efficacy profile of repaglinide and voglibose on targeting post prandial hyperglycemia in patients with newly diagnosed type II diabetes mellitus Jyoti Bobde*, Rajesh Kadam, Deepak Bhosle INTRODUCTION Diabetes mellitus is the single most important metabolic disease recognized worldwide as one of the leading causes of death and disability. 1 It is characterized by hyperglycemia and altered metabolism of lipids, proteins and carbohydrates. It mainly occurs due to absolute or relative deficiency of insulin along with the component of insulin resistance. 2 Currently, there is a growing interest in diabetes, as reported by International Diabetic Federation (IDF), an estimated 387 million people worldwide have diabetes in 2014 and this number is projected to reach a huge number of patients i.e. 592 million in 2035. While, IDF reported 66.8 million people of India are affected by diabetes in 2014. 3 Postprandial hyperglycemia is one of the earliest abnormalities of glucose homeostasis associated with type II DM and is markedly exaggerated in diabetic patients with fasting hyperglycemia. 4 Recent studies have shown that postprandial hyperglycemia is more accurate predictor of HbA1c levels and cardiovascular mortality than fasting ABSTRACT Background: In India the number of people with diabetes is increasing day-by- day. Due to a sole “Asian Indian Phenotype,” Indians develop diabetes an era earlier and have an earlier onset of complications. Therefore, it is essential to evaluate more effective treatment strategies at an earlier stage of disease progression. Methods: The present study was prospective, open label, comparative, randomized, parallel group, single center study. Comparison of two post prandial active treatment groups over a period of 3 months. Sixty patients of either sex in the age group of 30-60years with newly diagnosed type II diabetes mellitus, with prandial blood glucose levels >180mg% and <250mg% at screening as per ADA. The effect of repaglinide and voglibose were observed on various parameters i.e. HbA1c, FBS, PBS, BMI. Results: In repaglinide group the mean change in HbA1c from baseline to 3 months was 8.05 to 7.04 (-1.01); on the other hand, in voglibose group from baseline to 3 months was 8.0 to 7.18 (-0.82). Whereas, FBS from 137.57 to 122.90 (-16.67) in repaglinide group; in voglibose group from 139.87 to 125.13 (-14.74). Repaglinide statistically highly significant than voglibose group in improving glycemic indices. Conclusions: Though repaglinide and voglibose were equally effective in improving glycemic indices yet repaglinide showed better results in improving HbA1c, FBG, PBS as compared with voglibose. Repaglinide had minimal side effects as compared to voglibose. Keywords: Repaglinide, Type II diabetes mellitus, Voglibose DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20184840 Department of Pharmacology, MGM Medical College, Aurangabad, Maharashtra, India Received: 27 September 2018 Accepted: 25 October 2018 *Correspondence to: Dr. Jyoti Bobde, Email: drdeepakbhosle@ gmail.com Copyright: © the author(s), publisher and licensee Medip Academy. This is an open- access article distributed under the terms of the Creative Commons Attribution Non- Commercial License, which permits unrestricted non- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.